Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 6Thoracic 5Other solid neoplasm 3Gynecologic 2Genitourinary 2CNS 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Advanced Solid Tumor 3

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × cediranib × Other solid neoplasm × Clear all
NCT00502567 2011-07-27

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

AstraZeneca

Phase 1 Completed
104 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT00501605 2011-01-21

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

AstraZeneca

Phase 1 Completed
80 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT00503477 2009-06-12

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

AstraZeneca

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡